scientist | incurably interested | physics X microbes X medicines!
Boston, MA
Joined April 2022
- Tweets5
- Following68
- Followers31
- Likes4
Rajita Menon retweeted
We published in @JAMA_current the results of a randomized Phase 2 study of @vedantabio鈥榮 lead candidate VE303 for prevention of recurrent C. difficile infection (rCDI) 馃憠馃У/1
Among adults with laboratory-confirmed Clostridioides difficile infection (CDI) with 1 or more prior CDI episodes in the last 6 months and those with primary CDI at high risk for recurrence, high-dose VE303 prevented recurrent CDI vs placebo. ja.ma/3ohZHVZ #ECCMID2023
An exciting day at Vedanta with the launching of our large-scale manufacturing facility! We're ready to make lots and lots of bug-drugs.
Consistent large-scale cGMP production of defined bacterial consortia will be critical for late stage clinical studies and commercialization of #microbiome therapies. Today we launched a state-of-the-art manufacturing facility to bridge this gap bit.ly/39XUpZd
Last day at #DDW2022! Had a great time this morning sharing our work to understand why the VE303 higher dose elicits a better clinical response in C. difficile patients.
Recently we published Ph 1 results in healthy volunteers of our defined bacterial consortium VE303 that informed rational dose selection. Today, at #DDW22, we present data showing that VE303 is efficacious in Ph 2 and that higher dose 鉃★笍 better colonization 鉃★笍 higher activity
Rajita Menon retweeted
Recently we published Ph 1 results in healthy volunteers of our defined bacterial consortium VE303 that informed rational dose selection. Today, at #DDW22, we present data showing that VE303 is efficacious in Ph 2 and that higher dose 鉃★笍 better colonization 鉃★笍 higher activity
Today we published at @cellhostmicrobe the results of a Phase 1 study of @vedantabio鈥榮 lead candidate VE303 (for C. difficile infection), with a focus one studying pharmacokinetics (PK) and pharmacodynamics (PD) of this defined bacterial consortium. bit.ly/3KE85Wo馃У /1
